Context: Transition of diabetic patients from iv insulin infusion to s.c. insulin frequently results in rebound hyperglycemia.
Objectives: We hypothesized that initiation of a long-acting insulin therapy concurrently with i.v. insulin infusion would decrease the rate of rebound hyperglycemia after discontinuation of the insulin infusion.
Design And Intervention: Sixty-one diabetic patients receiving i.v. insulin therapy participated in this prospective randomized study. Subjects in the intervention group received daily injections of glargine s.c. (0.25 U/kg body weight) starting within 12 h of initiation of i.v. insulin infusion. Capillary blood glucose measurements were obtained up to 12 h after discontinuation of insulin infusion. Rebound hyperglycemia was defined as a blood glucose level greater than 180 mg/dl.
Setting: The study was conducted at the University of Colorado Hospital.
Patients: Sixty-one hospitalized patients with known type 1 or type 2 diabetes receiving i.v. insulin infusion participated in the study.
Main Outcome: The primary outcome of this study was to compare the rates of rebound hyperglycemia between the control and the intervention groups after i.v. insulin infusion is discontinued.
Results: Overall, 29 subjects in the control group (93.5%) had at least one glucose value above 180 mg/dl during the 12-h follow-up period. This was significantly greater than the rate of rebound hyperglycemia in the intervention group (10 subjects or 33.3%, P < 0.001). The effect of the intervention was apparent in subjects who presented with diabetic ketoacidosis, after solid organ transplantation, and in patients with other surgical and medical diagnoses. There were three hypoglycemic measurements in two control subjects (68, 62, and 58 mg/dl) and none in the intervention group.
Conclusions: Once-daily s.c. insulin glargine administered during i.v. insulin infusion is a safe method for preventing future rebound hyperglycemia, without increased risk of hypoglycemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2012-1244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart.
Clin Pharmacol Drug Dev
January 2025
BGL, BioGenomics Ltd, Maharashtra, India.
Insulin aspart, a rapid-acting analog, achieves faster subcutaneous absorption than regular insulin. This study aimed to demonstrate equivalence in the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of Recombinant Human Insulin Aspart from BioGenomics Limited (as test) and Novo-Nordisk (as reference) in healthy adult males. This was a double-blind, randomized, cross-over study, assessing PK and PD parameters under fasting conditions.
View Article and Find Full Text PDFPostprandial Hypoglycemia in a Patient With Clinical Beckwith-Wiedemann Syndrome.
JCEM Case Rep
January 2025
Department of Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
A male neonate exhibited hallmark features of Beckwith-Wiedemann syndrome (BWS) including large for gestational age, macroglossia, multiple ear pits, and umbilical hernia. He had neonatal hypoglycemia, requiring a glucose infusion rate of 9.7 mg/kg/min.
View Article and Find Full Text PDFThe Use of MiniMed780G System Is Associated With Stable Glycemic Control in People With Type 1 Diabetes Before, During, and After Ramadan: An Observational Study.
J Diabetes Res
January 2025
Diabetes Center, Dallah Hospital, Riyadh, Saudi Arabia.
The study was aimed at assessing the role of the MiniMed780G system of glycemic control before, during, and after Ramadan among people with Type 1 diabetes (PwT1D). This is a single-center retrospective analysis of MiniMed780G system users aged 14 years and above whose glycemic profiles were collected from February 21 to May 20, 2023, which corresponds to the Hijri months of Sha'ban, Ramadan, and Shawwal 1444/1445. Data was collected, processed, and analyzed in the framework of the Medtronic Galaxy service of the One Hospital Clinical Service (OHCS) program in Dallah Hospital, Riyadh, Saudi Arabia.
View Article and Find Full Text PDFA Case of Euglycemic Ketoacidosis Secondary to Continuous Renal Replacement Therapy.
Case Rep Crit Care
January 2025
Division of Pulmonary, Critical Care & Sleep Medicine, Keck Hospital of USC, Los Angeles, California, USA.
Euglycemic ketoacidosis (EKA) has been reported as a rare but life-threatening complication of continuous renal replacement therapy (CRRT). EKA should be suspected in the setting of persistent high anion gap metabolic acidosis despite renal replacement therapy. Critically ill patients, especially those with diabetes mellitus, are at risk of EKA due to deficient caloric intake, the presence of excess counterregulatory stress hormones, and nutritional losses from CRRT.
View Article and Find Full Text PDFProline enhances the hepatic induction of lipogenic gene expression in male hepatic fasn reporter mice.
Biochem Biophys Res Commun
January 2025
Department of Physiology and Metabolism, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, 920-8640, Kanazawa, Ishikawa, Japan; Metabolism and Nutrition Research Unit, Institute for Frontier Science Initiative, Kanazawa University, 13-1 Takaramachi, 920-8640, Kanazawa, Ishikawa, Japan. Electronic address:
Hepatic de novo lipogenesis (DNL) is increased by both carbohydrate intake and protein consumption. In hepatic fat synthesis, a key role is played by the induction of the hepatic expression of lipogenic genes, including Fasn, Scd1, and Srebf1. Regarding carbohydrate intake, increased blood glucose and insulin levels promote the expression of hepatic lipogenic genes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!